The results indicated that the sensitivity of sorafenib, nilotinib, lapatinib, gefitinib, erlotinib, dasatinib, and AKT inhibitor VIII were higher in high-risk group, whereas the sensitivity of bortezomib, doxorubicin, midostaurin, shikonin and tipifarnib were higher in low-risk group (Figure 8), which is valuable for exploring individualized chemotherapy for HCC patients in high-risk and low-risk groups. Here, AKT1 is linked to hepatocellular carcinoma.